Inhibiting any of a dozen different oncogenic pathway components, including EGFR, PI3K and MMP-9, could revert breast cancer cells (Figure 1a–1c) (Bissell et al., 2005; Beliveau et al., 2010; Becker-Weimann et al., 2013). The gene discussed is EGFR; the disease is breast cancer.